Ignite Creation Date:
2025-12-25 @ 2:42 AM
Ignite Modification Date:
2026-03-06 @ 12:07 PM
Study NCT ID:
NCT02869633
Status:
COMPLETED
Last Update Posted:
2023-10-23
First Post:
2016-08-10
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Sponsor:
Vanderbilt-Ingram Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Blastoid Variant Mantle Cell Lymphoma | View |
| None | Recurrent Chronic Lymphocytic Leukemia | View |
| None | Recurrent Follicular Lymphoma | View |
| None | Recurrent Hodgkin Lymphoma | View |
| None | Recurrent Mantle Cell Lymphoma | View |
| None | Refractory Chronic Lymphocytic Leukemia | View |
| None | Refractory Follicular Lymphoma | View |
| None | Refractory Hodgkin Lymphoma | View |
| None | Refractory Mantle Cell Lymphoma | View |
Keywords: